B
Bright Peak Therapeutics
Developing next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases
About Bright Peak Therapeutics
Bright Peak Therapeutics is at the forefront of developing next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases. Utilizing a proprietary chemical protein synthesis platform, the company engineers multifunctional precision biologics designed to enhance immune responses. Bright Peak's business model revolves around advancing a robust portfolio of cytokine-based therapies, targeting both innate and adaptive immune systems. The company operates in the biopharmaceutical sector, serving healthcare providers and patients seeking advanced treatment options. Revenue is generated through the development and potential commercialization of these novel therapies. With operations in Basel, Switzerland, and Southern California, Bright Peak is committed to expanding its international presence and continues to recruit talent to support its growth. The company's strategic focus on protein engineering positions it as a key player in the immunotherapy market. Keywords: immunotherapy, protein synthesis, cytokine, cancer treatment, autoimmune diseases, biologics, immune response, biopharmaceutical, precision medicine, healthcare.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 62.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Autoimmune, Precision Medicine, Immune System, Immunotherapy, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2024 | $90M | $535M | Fidelity Investments · Invus · Northleaf · RA Capital Management | ↗ |
| SERIES BOther financing | Jun 2021 | $107M | $428M | Alexandria Venture Investments · BlackRock · Fidelity Investments · Qatar Investment Authority | — |
Growth signals
Latest recorded traffic for Bright Peak Therapeutics is 670 monthly website visits, down 70.9% over the last three months. Bright Peak Therapeutics's team declined 22.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Versant Ventures
RA Capital Management
Alexandria Venture Investments
BlackRock
Fidelity Investments
Qatar Investment Authority
Invus
Series B and later4 investors entered at this stage
Johnson & Johnson Innovation
Northleaf
KB Investment
Venrock
Other known investors1 additional known investor
ETH Zurich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bright Peak Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bright Peak Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.